Monovalent Anti-ILT5 Antibody T Cell Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively induce immunostimulatory effects or inhibit T cell responses in a controlled manner, particularly in the context of antigen-presenting cells (APCs) and T cells, which is crucial for treating diseases and enhancing immune responses.
Innovation Solution
The use of anti-ILT5 antibodies and ILT5-binding fragments, specifically in monovalent form, to contact antigen-presenting cells (APCs) to induce T cell proliferation, cytotoxic potential, and immune responses, or in crosslinked form to inhibit T cell responses, thereby modulating immune activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to induce T cell responses, then T cell proliferation and immune responses can be achieved, but the control and modulation of these responses are insufficient
Solution Approach 1:
The patent utilizes different valency states (monovalent vs. crosslinked forms) of anti-ILT5 antibodies to modulate T cell responses. By changing the physical and chemical parameters of the antibody (valency, crosslinking status), the system achieves controlled modulation of T cell proliferation and immune responses, resolving the contradiction between control reliability and response efficiency
Solution Approach 2:
The anti-ILT5 antibody serves as an intermediary molecule that mediates the interaction between APCs and T cells. By introducing this specific antibody that targets ILT5 on APCs, the patent achieves precise control over T cell activation, enabling reliable modulation of immune responses while maintaining efficient T cell proliferation
2Productivity
If monovalent anti-ILT5 antibodies are used to contact APCs, then T cell proliferation and cytotoxic potential are induced, but the ability to inhibit T cell responses is reduced
Solution Approach 1:
The patent employs dynamic switching between different antibody forms (monovalent for stimulation, crosslinked for inhibition) to adapt the immune response modulation to therapeutic needs. This dynamic approach allows the system to transition between inducing T cell proliferation and inhibiting T cell responses based on the specific therapeutic context
Solution Approach 2:
The anti-ILT5 antibody system exhibits multi-functionality by being able to both induce and inhibit T cell responses depending on its valency state. The same antibody target (ILT5) and antibody type can be used for either stimulating or suppressing immune responses, providing universal applicability across different therapeutic scenarios
Data Source
AI summary
Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.